17th Annual Bio Innovation Leaders Summit 2025
12th & 13th February 2025
Raffles Singapore
BILS 2026 ·
Bio Innovation Leaders Summit 2026
11th & 12th February 2026
Royal Lancaster Hotel
Lancaster Terrace, London
Located with CGTI.ai 2026
New Frontier of Biomanufacturing.
BILS convenes the leaders responsible for how biologics actually run. Governed, not guessed.
Designed for precision, sustainability and growth.
From stainless to single-use, from batch to continuous — bioprocess technology has moved.
One constraint has not: biomanufacturing must be predictable, auditable and explainable before anyone will sign.
Heads of Manufacturing. MSAT. CMC. Technical Operations. The decisions that govern tech transfer, batch records, deviations and release.
This year, BILS includes a 90-minute AIO feature.
AI officers and data leaders in the same room as the people who own operational accountability.
One question at the centre:
what would it take for you to sign your name on this decision?
For the few.
BILS is where bioprocess leadership meets biomanufacturing reality.
Governed, not guessed.
BILS 2026 is invitation‑only for COOs, SVPs and Heads of Manufacturing, MSAT, CMC, Technical Operations, Digital/AI and Quality at global biopharma and CDMOs – the people who sign for cost, compliance and supply when AI touches production
The Imperative
From stainless and single‑use to intensified and continuous, one constraint now cuts across every biologics portfolio: production must be predictable, auditable and explainable before anyone is willing to sign. BILS exists to close that gap by putting biologics leaders in the same room as AIO – the officers who decide how far AI and data are allowed into biomanufacturing – and by bringing together Heads of Manufacturing, MSAT, CMC, Technical Operations and Digital leaders to examine what is actually running in commercial biologics today, what regulators will accept and what they still do not trust AI to do
Most biologics fail or stall in CMC and manufacturing, not in discovery and the gap between promising data and reliable supply is widening.
As restructurings and job cuts ripple through biopharma, investment is flowing into automation, ML, and AI, raising the bar for how transparently those systems must perform in validated production.
BILS exists to close that gap by putting biologics leaders in the same room as AIO: the officers who decide how far AI and data are allowed into biomanufacturing
Chief Operating Officers -transformation, scale, operating model
Heads of Manufacturing, MSAT and CMC - process design, tech transfer, validation
Leaders in Data, AI and Automation - digital twins, advanced analytics, manufacturing IT
Quality and Regulatory Executives - QA, QMS, GxP, regulatory strategy
Biologics manufacturing is under pressure from every direction.
Capacity demands. Cost discipline. Regulatory expectations. Digital transformation promises that outpace validation realities.
Leaders are asked to modernise without disrupting. To adopt AI without losing explainability. To compress timelines without compromising quality.
The answers do not live in vendor demos or consulting decks.
They emerge when operations leaders share what is actually working — and what is not.
Senior leaders responsible for how biologics are manufactured, transferred and released:
-
Heads of Manufacturing and Bioprocessing
-
MSAT and Tech Transfer Directors
-
CMC and Process Development Leaders
-
VP Quality and Regulatory Operations
-
Digital, Automation and Data Officers
The people who make production predictable, auditable and explainable.
Intelligence
AI that turns bioprocess data into decisions across biologics, advanced therapies and future food.
Capacity the planet can afford, from biologics plants to protein bioreactors.
Architectures that make every batch count, whether it becomes a drug or a dinner.
New modalities and new menus that survive scale‑up, not just slides
Architectures that make every batch count.
Leaders who build them.
Our 2026 Gathering is Curated For
Audience
Chief Operating Officers -transformation, scale, operating model
Heads of Manufacturing, MSAT and CMC - process design, tech transfer, validation
Leaders in Data, AI and Automation - digital twins, advanced analytics, manufacturing IT
Quality and Regulatory Executives - QA, QMS, GxP, regulatory strategy
Also Welcome
Chief Data and Technology Officer
Head of Manufacturing IT/OT
VP Supply Chain and Logistics
Head of Cold Chain and Distribution
VP Quality Assurance
VP Regulatory Affairs
Head of Compliance and Release CDMO executives: EVP Operations, Head of Client Programs
Why They Gather
Science moves faster than the systems built to sustain it.
Applied intelligence turns information into infrastructure and links algorithms to execution - AI, automation and digital twins as living systems that learn and improve.
For biopharma it enables real-time oversight, continuous validation and reliability across networks.
For CGT it bridges innovation and access at scale without losing purpose.
SPEAKERS
Judy Chou
President and CEO of AltruBio
Uwe Gottschalk
Operating Partner at Keensight Capital
Nuno Fontes
SVP, Head of Global CMC at WuXi Biologics
BILS 2026 | AIO
The Four Pillars of Intelligent Biomanufacturing
1. Intelligence
From data to insight. From insight to action.
Where real-time analytics, predictive modelling and AI-driven process understanding accelerate decision-making across development, CMC and manufacturing.
Why it matters: Speaks to leaders shaping intelligent operations - turning complex data into scalable strategy and measurable performance.
2. Integration
From silos to systems.
Unifying development, production and supply through connected digital ecosystems that align process, technology and quality.
Why it matters: Reflects the pursuit of digital maturity and cross-functional harmony - essential for organisations building end-to-end visibility across biomanufacturing networks.
3. Infrastructure
Where design, quality and automation converge.
A modernised operational backbone where QMS, GxP and validation meet agility through digital twins, modular platforms and intelligent control.
Why it matters: Captures the transformation of biomanufacturing - blending regulatory precision with design thinking and speed to enable compliant, adaptive systems.
4. Impact
From innovation to implementation.
Where science becomes outcomes that improve lives and sustain progress across global manufacturing and supply networks.
Why it matters: Grounds intelligent operations in real-world value - ensuring innovation reaches patients through reliable, scalable and sustainable execution.
Voices of Influence. Leaders of Impact.
ADVISORY
Leadership that shape the future of biologics manufacturing and guide the next decade of innovation.
INVITED ONLY AUDIENCE
The next biologics plant won’t be run by more people.
It will be run by AI and digital twins leaders are willing to validate and defend.
SUMMIT
INSIGHTS
Our Mission
Our purpose is to create a gathering that empowers and inspires critical decision-making; sparking new opportunities to amplify their impact within the biologics and cell and gene therapy value chain.
We encourage collaboration and innovation, which is why this summit ensures that each participant contributes significantly to advancing the field. It serves as a platform for sharing insights, fostering partnerships and driving forward the next wave of breakthroughs in biologics.
For the patients, we must do better.
Investors and large biopharma companies need to satisfy environmental compliance. We will keynote the progression toward more sustainable bioprocesses, manufacturing and supply methods, amalgamating toward building a sustainable and digitised ecosystem - an emerging frontier of digitisation and industry 4.0.
Closing session by Merck.
Attendee Profile
C-Suite - Directors - Executives
Bioprocess - Manufacturing - IT-Data Integration - Commercial and Business Development - Scientists - Supply Chain - Production - PAT
Focus Area
CGT
Antibody Drugs
Vaccine
Small molecule, conjugates and peptides
Technology or Service Companies
CRO
CDMO
Biologic workflow solutions
Advance Bioprocessing
End to end workflow solutions
Digitising - AI - Data
Automation - Robotics
Filtration - Single use - Bioreactors
Event highlights
Pre Event Innovation Tour - Private Innovation Tour - CXO
Please click to Tour 2024
Evening of day one -Private Networking Dinner
Journey of a CXO
Exclusive closed-door talks from some of the most prominent leaders in the industry who will be talking about their journey, lessons learnt and vision for the future.
Attendance Guide
30% Asian Biopharma
25% International Biopharma
20% CMOs - CDMOS's
15% Academic & Research Institutes
10% Technology & Service Providers
Curated Meetings
Packages have sold out
Guaranteed pre-qualified strategy meetings
Prior contact
Mutual benefit
Conducted by our specialists
Geography
25% Korea & Japan
20% Singapore
20% Indonesia, Thailand, Philippines, Malaysia, India & Australia
15% China, Hong Kong & Taiwan
15% USA
5% UAE
Joshi Venugopal
GM & Head of Europe
Novartis Gene Therapies & Rare Diseases
Dorothee Ambrosius
Former Head of CMC Strategy Biologicals
Boehringer Ingelheim
Warner Biddle
Former Global Head of Commercial
Kite, a Gilead Company
Gwendolyn Binder
President of Science & Technology
Cabaletta Bio
Pierre Caloz
COO
uniQure
Paolo Martini
Former CSO
Moderna
CURRENT SPEAKERS
PREVIOUS SPEAKERS
